DENARASE®- Precision Nuclease for Cleaner Bioprocessing
Supplied by Verified
c-LEcta GmbH
View supplier profile
c-LEcta GmbH · Verified supplier

DENARASE®- Precision Nuclease for Cleaner Bioprocessing

SKU BHZ16500001
In StockBest SellerFeaturedGMP AvailablePeer-ReviewedFree Sample

Products for use in research and development & GMP For process development and GMP manufacturing of biologicals such as viral vectors and vaccines. Removing all forms of DNA and RNA, DENARASE® enhables a simpler, more efficient downstream process. DENARASE® GMP-grade is manufactured under EU GMP conditions DENARASE® R&D-grade is produced in conformity with the ISO 9001 standard, with less strict requirements regarding documentation, storage and distribution From a technical performance perspective, both quality grades are equal and the parameters on the specification are the same. This allows for a seamless transition from early R&D stage towards biopharmaceutical manufacturing under GMP.

Promotion 10% off your first orderNew customers save 10% on any R&D-grade DENARASE® product.CodeDENARASE10 View offer →
At a glance
Purity
≥ 99%​
Activity
> 250 U/µl​
Formulation
Buffered aqueous glycerol solution
Storage Temperature
-20°C
See all 6 configurations
All configurations · 6 options
Catalog No.SizeQuality GradeAvailability Price Qty Order
20804-100K100 kUR&DIn Stock $599.50
Quote
20804-500K500 kUR&DIn Stock $1,831.50
Quote
20804-1000K1000 kUR&DIn Stock $2,673.00
Quote
20804-5000K5000 kUR&DIn Stock $8,948.50
Quote
20804-1M1 MUGMPIn Stock at Manufacturer $3,156.00
Quote
20804-5M5 MUGMPIn Stock at Manufacturer $10,573.00
Quote
R&D grade: in stock, ships in 2–3 business days. GMP grade: in stock at the manufacturer, 1–2 weeks. Shipped under qualified cooled conditions; transit temperature may differ from storage temperature without affecting quality. −20 °C ± 5 °C. Do not store at −70 °C or below — deep freezing causes loss of activity. Shipping calculated at checkout · card orders +3% · Sales terms & conditions — please review before ordering. For Research Use Only. Not for diagnostic or therapeutic use.
Questions? Talk to us 1-866-986-9598 orders@biohippo.com

Overview

What is denarase®- precision nuclease for cleaner bioprocessing?

About DENARASE®

How DENARASE® works

DENARASE® specifically hydrolyzes the phosphodiester bonds between nucleotides, leaving smaller fragments of around 3–5 base pairs. The enzyme is active on all forms of nucleic acids including single-stranded, double-stranded, linear, circular, or supercoiled. Best results are obtained when the enzyme is added before the release of DNA.


Production of DENARASE®

DENARASE® has been developed for use in commercial manufacturing processes of biologicals and complies with EU GMP regulations. The production process uses a gram-positive Bacillus sp. production host, which minimizes the risks of endotoxins in the product. No antibiotics, Triton X-100, materials with TSE/BSE risk, or raw materials of animal origin are employed in the manufacture of the product.


DENARASE® is available in two quality grades

DENARASE® for Research and Development (R&D) use & DENARASE® for manufacturing under GMP.

  • DENARASE® R&D-grade is produced in conformity with the ISO 9001 standard, with less strict requirements regarding documentation, storage, and distribution.
  • DENARASE® GMP-grade is manufactured under EU GMP conditions.
  • From a technical performance perspective, both quality grades are equal and the parameters on the specification are the same. This allows for a seamless transition from early R&D stage towards biopharmaceutical manufacturing under GMP.
  • In order to avoid mix-ups, packaging units of the same size are indicated differently in the product name of the two quality standards: 1,000 / 5,000 kU for R&D-grade DENARASE® and 1 / 5 MU for GMP-grade DENARASE®.



Details

Specifications

Alternative namesAlso referred to by the manufacturer as wild-type DENARASE® — the standard, non-engineered variant, distinguishing it from the engineered DENARASE® High Salt. Serratia marcescens endonuclease. Manufacturer catalogue prefix 20804.
UniProt #P13717
SpeciesSerratia marcescens (enzyme origin)
ApplicationsViral Vector Production, Vaccine Production, Host Cell DNA Removal, VLP Production, Biofilm Removal, Protein Purification, Downstream Bioprocessing
Expression systemRecombinant, Bacillus sp. (gram-positive)
SourceRecombinant endonuclease expressed in a gram-positive Bacillus sp. host, avoiding the endotoxin burden of gram-negative expression systems. Produced without animal-derived raw materials, antibiotics or Triton X-100.
Molecular weight27 kDa (per monomer, calculated)
Protein length27 kDa (per monomer)
Purity≥ 99% (SDS-PAGE, silver staining)
Biological activitySpecific activity > 6 × 10⁵ U/mg
Activity> 250 U/µL
Enzyme typeEndonuclease, Serratia marcescens nuclease
Endotoxin level< 0.25 EU/kU (LAL, Ph. Eur. 2.6.14 Method C)
SterilityTotal microbial count per Ph. Eur. 2.6.12 — aerobic bacteria < 5 cfu/200 µL; yeast and moulds < 5 cfu/200 µL. No protease activity detectable.
Animal origin-freeYes — produced without animal-derived raw materials; no TSE/BSE risk
Antibiotic-freeYes — produced without antibiotics and without Triton X-100
Concentration> 250 U/µL
FormulationBuffered aqueous glycerol solution
pHpH optimum 8.0–9.0; active across pH 7.4–9
FormLiquid solution
PackagingNon-pyrogenic, USP Class VI compliant vials; sealed secondary packaging with tamper-evident seals
Storage−20 °C ± 5 °C. Do not store at −70 °C or below — deep freezing causes loss of activity.
Shelf lifeAt least 36 months from date of manufacture / product release
ShippingR&D grade: in stock, ships in 2–3 business days. GMP grade: in stock at the manufacturer, 1–2 weeks. Shipped under qualified cooled conditions; transit temperature may differ from storage temperature without affecting quality.
Unit of measure1 U digests salmon sperm DNA to acid-soluble oligonucleotides equivalent to ΔA₂₆₀ of 1.0 in 30 min at pH 8.0, 37 °C
Main SKUBHZ16500001

Applications

Applications & how to use

Viral Vector Production

Upstream manufacture of AAV, lentiviral and adenoviral vectors in producer lines such as HEK 293. Raw materials used at this stage must carry documentation suitable for regulatory submission.

Vaccine Production

Propagation of vaccine substrates in cell lines such as Vero and MDCK. Animal origin-free processing aids reduce adventitious-agent risk and simplify the regulatory dossier.

Host Cell DNA Removal

VLP Production

Biofilm Removal

Protein Purification

Separating a target protein from a complex mixture while keeping it folded and active, using chromatography, spin columns, selective binding or buffer exchange. Recovery and retained activity matter more than purity alone, so an activity assay should accompany the gel at each step.

Downstream Bioprocessing

Evidence

Validation & QC

Validation data for this product isn’t published yet.

Need specific QC or validation results — titer, purity, endotoxin, or assay data — for your application? Our scientific team can share what is available for this product and lot on request.

Request validation data

Manufacturing

How it's made & quality control

Supplier quality control

Batch release specification

\nAppearance: clear, transparent solution. Activity above 250 U/µL by photometric assay. Purity ≥ 99% (standard DENARASE®) or ≥ 98% (High Salt) by SDS-PAGE with silver staining. Specific activity above 6 × 10⁵ U/mg. No protease activity detectable. Endotoxin below 0.25 EU/kU by LAL per Ph. Eur. 2.6.14 Method C. Microbial count per Ph. Eur. 2.6.12: aerobic bacteria and yeast or moulds each below 5 cfu per 200 µL.

Clearance validation

\nThe DENARASE® ELISA Kit is a monoclonal antibody-based sandwich ELISA for residual Serratia marcescens endonuclease in process samples, covering standard DENARASE®, DENARASE® High Salt and Benzonase®. Limit of detection 4 pg/mL, limit of quantification 12 pg/mL, working range approximately 32–1,000 pg/mL, assay time approximately 130 minutes. For High Salt, apply a correction factor of 1.46. Benzonase® is a registered trademark of Merck KGaA.

Documents available

\nProduct Information Sheets and Product Specifications for R&D and GMP grades; Validation Guide; guidance on qualifying DENARASE® in biopharmaceutical manufacturing; Change Guidance Document for grade transition; US FDA Drug Master File support documentation; ELISA Kit user instructions, kit contents and prevalidation report.

Supplier-level quality statement. For lot-specific results, request the Certificate of Analysis for your batch.

Questions

Frequently asked questions

What are the key benefits of using DENARASE®?

Reliable, economical DNA clearance across a broad salt spectrum and pH range.
High activity on all forms of DNA and RNA.
Produced under GMP conditions in accordance with EU GMP regulations.
R&D and GMP grades with equivalent performance.
Manufactured free of animal-derived materials, antibiotics and Triton X-100.
Endotoxin-free expression host.
Companion one-for-all Serratia marcescens ELISA Kit for clearance validation.

Is DENARASE® a cost-efficient alternative to Benzonase® for AAV and other bioprocess applications?

A peer-reviewed study on AAV production (Nascimento et al., Journal of Biotechnology, Vol. 408, 72–79, December 2025, doi: 10.1016/j.jbiotec.2025.09.002) used DENARASE® as a more economical solution compared with Benzonase®. Efficiency depends on buffer composition, dosing, scalability and downstream design, so results will vary between processes — small-scale feasibility testing is recommended before switching.

What is the delivery time for DENARASE® products?

R&D grade is held in US stock and ships in 2–3 business days. GMP grade is held at the manufacturer, typically 1–2 weeks.

What can DENARASE® be used for?

DENARASE® hydrolyses phosphodiester bonds between nucleotides, leaving fragments of roughly 3–5 base pairs. It is active on all nucleic acid forms — single- and double-stranded, linear, circular and supercoiled — and is widely used in research, process development, and production of viral vectors and vaccines.

What are the recommended usage conditions?

Peak performance at low to physiological salt: recommended for use below 150 mM NaCl. Release assay conditions are 0 mM NaCl and 1 mM MgCl2. Recommended starting concentration is 10–100 U/mL; optimise incubation time, enzyme concentration and temperature for your own process.

What are the main application fields?

Viral vector production (AAV, lentivirus, HEK293): added during or after cell lysis to reduce viscosity, degrade nucleic acids and simplify downstream purification.
Vaccine manufacturing (live attenuated, inactivated, VLP): reduces host cell DNA during harvest, improves process robustness and helps prevent aggregation.

Are there different quality grades?

Two grades, technically equivalent and released against the same specification parameters. R&D grade is produced under ISO 9001 with less strict documentation, storage and distribution requirements. GMP grade is manufactured under EU GMP with US FDA Drug Master File support and GDP-compliant distribution.

What should I consider when comparing DENARASE® and Benzonase® performance?

c-LEcta has published a comparative study using the DENARASE® activity release test to compare both enzymes directly — useful when establishing a dual-sourcing strategy. Data is available via the downloads section. Benzonase® is a registered trademark of Merck KGaA.

Does the DENARASE® ELISA Kit also detect Benzonase®?

Yes. The DENARASE® ELISA Kit quantifies DENARASE®, DENARASE® High Salt and Benzonase® in a single assay for residual Serratia marcescens endonuclease monitoring, with a limit of detection of 4 pg/mL and a limit of quantification of 12 pg/mL. Benzonase® is a registered trademark of Merck KGaA.

How can DENARASE® be removed from my process?

Anion exchange, cation exchange, hydrophobic interaction, hydroxyapatite or size exclusion chromatography, and filtration techniques. The appropriate media should be evaluated case by case.

How can enzyme activity be inhibited?

Approximately 600 mM NaCl is sufficient. Potassium phosphate at 200–300 mM can also quench activity depending on buffer composition, and EDTA above 5 mM inhibits the reaction by removing free magnesium ions.

Are DENARASE® products tested for endotoxins?

Yes. Every batch must meet the endotoxin specification of less than 0.25 EU/kU before release, tested by LAL assay according to Ph. Eur. 2.6.14 Method C. See the Validation Guide for full details.

Answered by our team

Questions from researchers

No researcher questions have been answered for this product yet. Ask our technical team and we'll get back to you — approved answers are published here.

Ask our technical team

Reviewed by a scientist — typically answered within one business day.

Deals

Promotions

Codes apply at checkout
Matches this product
15%OFF
15% Off Cancer Antibodies
Ends Sep 30 ONCO15
Matches this product
25 kUFREE
Free 25 kU Sample — DENARASE® & DENARASE® High Salt
FREESAMPLE
$50 OFF
$50 Off All ELISA Kits
Limited time ELISA50
10% OFF
10% OFF CELL LINES-Limited-Time Offer
Ends Sep 30 CELL10
FREE SAMPLE
Free Sample – CellTrypase Recombinant Trypsin-Like Enzyme
Limited time offer – availa... FREESAMPLE
FREE SAMPLE
Free Sample – MycoFold™ Growth Factors
Limited time offer – availa... Request Free Sample

References

Citations & references

DENARASE® Scientific Publications

A selection of peer-reviewed publications and reports referencing or featuring DENARASE®.

Viral Vectors for Gene Therapy and Vaccine Production

22 publications
Developing a robust and scalable platform for AAV8 production
Nascimento, André et al.
Journal of Biotechnology, Vol. 408, 72–79, December 2025 · doi: 10.1016/j.jbiotec.2025.09.002
View Publication →
Abundance-biased codon diversification prevents recombination in AAV production and ensures robust in vivo expression of functional FRET sensors
Dernic, Jan et al.
Communications Biology vol. 8,1 1244, 19 Aug. 2025 · doi: 10.1038/s42003-025-08677-6
View Publication →
Salt-tolerant endonucleases, the benefits for viral vector manufacturing and a comparison of two marketed enzymes
Marc Struhalla, Svenja Michalek
Cell & Gene Therapy Insights 2025; 11(3), 305–317, 26 March 2025 · doi: 10.18609/cgti.2025.035
View Publication →
Timed chromatin invasion during mitosis governs prototype foamy virus integration site selection and infectivity
Lagadec, Floriane et al.
Nucleic Acids Research vol. 53,10 gkaf449, 31 May 2025 · doi: 10.1093/nar/gkaf449
View Publication →
A two-pass anion-exchange chromatography strategy for enrichment of full capsids in manufacturing of adeno-associated viral vectors
Thakur, Garima et al.
Molecular Therapy. Methods & Clinical Development vol. 33,2 101441, 3 Mar. 2025 · doi: 10.1016/j.omtm.2025.101441
View Publication →
Recombinant AAV batch profiling by nanopore sequencing elucidates product-related DNA impurities and vector genome length distribution
Dunker-Seidler, Florian et al.
Molecular Therapy. Methods & Clinical Development 33,1 101417, 22 Jan. 2025 · doi: 10.1016/j.omtm.2025.101417
View Publication →
Polo-like kinase inhibitors increase AAV production by halting cell cycle progression
Fisher, Kaylin et al.
Molecular Therapy. Methods & Clinical Development vol. 33,1 101412, 17 Jan. 2025 · doi: 10.1016/j.omtm.2025.101412
View Publication →
Selective Enhancement of REM Sleep in Male Rats through Activation of Melatonin MT1 Receptors Located in the Locus Ceruleus Norepinephrine Neurons
López-Canul, Martha et al.
The Journal of Neuroscience vol. 44,29 e0914232024, 17 Jul. 2024
View Publication →
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand
Nicolai, Christopher J et al.
Blood vol. 144,9 (2024): 977–987
View Publication →
Unveiling the secrets of adeno-associated virus: novel high-throughput approaches for the quantification of multiple serotypes
Meierrieks, Frederik et al.
Molecular Therapy. Methods & Clinical Development vol. 31 101118, 2023
View Publication →
Scaling Up of Steric Exclusion Membrane Chromatography for Lentiviral Vector Purification
Labisch et al.
Membranes 13(2): 149 (2023)
View Publication →
Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing
Sonogür et al.
Molecular Biotechnology 65(7): 1129–1139 (2023)
View Publication →
Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing
Mekkaoui et al.
Molecular Therapy. Methods & Clinical Development 28: 116–128 (2022)
View Publication →
Comparison of the performance of anion exchange membrane materials for adenovirus purification using laterally-fed membrane chromatography
Kawka et al.
Biochemical Engineering Journal 182: 108417 (2022)
View Publication →
Steric exclusion chromatography of lentiviral vectors using hydrophilic cellulose membranes
Labisch et al.
Journal of Chromatography A 1674: 463148 (2022)
View Publication →
Integrated development of enzymatic DNA digestion and membrane chromatography processes for the purification of therapeutic adenoviruses
Kawka et al.
Separation and Purification Technology 254: 117503 (2021)
View Publication →
A new simplified clarification approach for lentiviral vectors using diatomaceous earth improves throughput and safe handling
Labisch et al.
Journal of Biotechnology 326: 11–20 (2021)
View Publication →
Scalable upstream process development for the suspension-based production of lentiviral vectors for CAR T cell therapies with multiparallel & benchtop bioreactor systems & DoE methodology
Riethmüller et al.
Cell & Gene Therapy Insights 7(6): 689–700 (2021)
View Publication →
Transfer and scale-up from 10 L BioBLU® to Allegro™ STR 50 and STR 200 Bioreactors
Mainwaring et al.
Cell & Gene Therapy Insights 7(9): 1347–1362 (2021)
View Publication →
Scalability comparison between 50 and 500 liter stirred tank bioreactor for production of rAAV viral vector
Sanderson et al.
Cell & Gene Therapy Insights 7(9): 1025–1033 (2021)
View Publication →
Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles
Hein et al.
BMC Biology 19(1): 91 (2021)
View Publication →
Highly Efficient Purification of Recombinant VSV-ΔG-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography
Lerer et al.
BioTech 10(4): 22 (2021)
View Publication →
A high cell density perfusion process for Modified Vaccinia virus Ankara production: Process integration with inline DNA digestion and cost analysis
Gränicher, Gwendal et al.
Biotechnology and Bioengineering 118(12): 4720–4734 (2021)
View Publication →

Production of Virus-like Particles (VLP)

10 publications
Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles
M. S. von Elling-Tammen
Journal of Chromatography B vol. 1256 124539, 2025 · doi: 10.1016/j.jchromb.2025.124539
View Publication →
Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation
Sherry, Lee et al.
NPJ Vaccines 10,1 64, 31 Mar. 2025 · doi: 10.1038/s41541-025-01111-2
View Publication →
Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells
Alpuche-Lazcano et al.
Communications Medicine 3(1): 116 (2023)
View Publication →
Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
Vrablikova et al.
Frontiers in Veterinary Science 10: 1116661 (2023)
View Publication →
Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate
Kingston et al.
bioRxiv (Preprint, 2023)
View Publication →
VelcroVax: a "Bolt-On" Vaccine Platform for Glycoprotein Display
Kingston et al.
mSphere 8(1): e0056822 (2023)
View Publication →
Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris
Sherry et al.
Viruses 14(10): 2159 (2022)
View Publication →
Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly
Sherry et al.
Microbiology Spectrum 11(1): e0430022 (2023)
View Publication →
Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection
Yilmaz et al.
Allergy 77(1): 258–270 (2022)
View Publication →
Separation of influenza virus-like particles from baculovirus by polymer-grafted anion exchanger
Reiter et al.
Journal of Separation Science 43(12): 2270–2278 (2020)
View Publication →

Production of Bacteriophages

2 publications
In situ targeted base editing of bacteria in the mouse gut
Brödel, Andreas K et al.
Nature vol. 632,8026 (2024): 877–884
View Publication →
Phage therapy potentiates second-line antibiotic treatment against pneumonic plague
Vagima et al.
Viruses 14(4): 688 (2022)
View Publication →

Biofilm Removal

2 publications
Targeting Staphylococcus aureus biofilm-related infections on implanted material with a novel dual-action thermosensitive hydrogel containing vancomycin and a tri-enzymatic cocktail: in vitro and in vivo studies
Buzisa Mbuku, Randy et al.
Biofilm vol. 9 100288, 20 May 2025 · doi: 10.1016/j.bioflm.2025.100288
View Publication →
Hydrolytic Enzymes as Potentiators of Antimicrobials against an Inter-Kingdom Biofilm Model
Ruiz-Sorribas et al.
Microbiology Spectrum 10(1): e02589-21 (2022)
View Publication →

Protein Purification

5 publications
Novel fold and wing structure of Forkhead transcription factor facilitate DNA binding
Wang, George L et al.
Nucleic Acids Research vol. 53,18 (2025): gkaf946 · doi: 10.1093/nar/gkaf946
View Publication →
Mapping the genetic landscape of iron metabolism uncovers the SETD2 methyltransferase as a modulator of iron flux
Martinelli, Anthony W et al.
Science Advances vol. 11,38 (2025): eadw9095 · doi: 10.1126/sciadv.adw9095
View Publication →
Granulins rescue inflammation, lysosome dysfunction, lipofuscin, and neuropathology in a mouse model of progranulin deficiency
Root, Jessica et al.
Cell Reports 43,12 (2024): 114985 · doi: 10.1016/j.celrep.2024.114985
View Publication →
Effective removal of host cell-derived nucleic acids bound to hepatitis B core antigen virus-like particles by heparin chromatography
Valentic, Angela, and Jürgen Hubbuch
Frontiers in Bioengineering and Biotechnology 12 1475918, 3 Oct. 2024 · doi: 10.3389/fbioe.2024.1475918
View Publication →
Deubiquitinating enzyme mutagenesis screens identify a USP43-dependent HIF-1 transcriptional response
Pauzaite, Tekle et al.
The EMBO Journal vol. 43,17 (2024)
View Publication →

Customization

Customization & add-ons

Many enzymes can be supplied in formats beyond the catalog listing — alternative grades (research versus GMP/manufacturing), glycerol-free or custom buffers, defined activity units or concentrations, and bulk or large-scale quantities. Custom formulation and packaging are available for selected products. Availability, minimum order quantities, and lead times vary by supplier. Tell us the enzyme, the grade, formulation, and activity you need, and the scale, and we’ll prepare a quote.
Talk to a scientist

Explore

Collections featuring this product

All collections

This product is included in the curated collections below. Browse a collection to source everything for a workflow from a single cart.

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today